$WLDS
Wearable Devices Ltd. Stock $wlds

$wlds Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023022124 Filed on March 22, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$45.00K	$45.00K	$142.0K
YoY Change	-68.31%	-68.31%	149.12%
Cost Of Revenue	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	11.11%
Gross Profit	$35.00K	$40.00K	$132.0K
YoY Change	-73.48%	-69.23%	175.0%
Gross Profit Margin	77.78%	88.89%	92.96%
Selling, General & Admin	$3.318M	$3.318M	$1.293M
YoY Change	156.61%	156.61%	180.48%
% of Gross Profit	9480.0%	8295.0%	979.55%
Research & Development	$2.271M	$2.271M	$1.411M
YoY Change	60.95%	60.95%	89.91%
% of Gross Profit	6488.57%	5677.5%	1068.94%
Depreciation & Amortization	$20.00K	$23.00K	$10.00K
YoY Change	100.0%	109.09%	0.0%
% of Gross Profit	57.14%	57.5%	7.58%
Operating Expenses	$6.493M	$5.589M	$2.801M
YoY Change	131.81%	106.69%	132.64%
Operating Profit	-$6.458M	-$6.458M	-$2.669M
YoY Change	141.96%	141.96%	130.88%
Interest Expense	-$38.00K	-$40.00K	$55.00K
YoY Change	-169.09%	-166.67%	-153.92%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.496M	-$6.500M	-$2.614M
YoY Change	148.51%	149.04%	107.79%
Income Tax
% Of Pretax Income
Net Earnings	-$6.496M	-$6.496M	-$2.614M
YoY Change	148.51%	148.51%	107.79%
Net Earnings / Revenue	-14435.56%	-14435.56%	-1840.85%
Basic Earnings Per Share		-$0.53
Diluted Earnings Per Share	-$0.53	-$0.53	-$176.2K
COMMON SHARES
Basic Shares Outstanding	15.05M shares	12.28M shares
Diluted Shares Outstanding		12.28M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.37M	$10.37M	$1.270M
YoY Change	716.54%	716.54%
Cash & Equivalents	$10.37M		$1.274M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$10.00K	$10.00K	$10.00K
Prepaid Expenses
Receivables	$0.00	$0.00	$10.00K
Other Receivables	$600.0K	$600.0K	$110.0K
Total Short-Term Assets	$10.98M	$10.98M	$1.402M
YoY Change	682.88%	684.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$68.00K	$250.0K	$43.00K
YoY Change	58.14%	525.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$248.0K	$240.0K	$43.00K
YoY Change	476.74%	380.0%
TOTAL ASSETS
Total Short-Term Assets	$10.98M	$10.98M	$1.402M
Total Long-Term Assets	$248.0K	$240.0K	$43.00K
Total Assets	$11.22M	$11.22M	$1.445M
YoY Change	676.75%	673.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$156.0K	$160.0K	$72.00K
YoY Change	116.67%	128.57%
Accrued Expenses	$145.0K	$630.0K	$47.00K
YoY Change	208.51%	133.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.150M	$1.150M	$638.0K
YoY Change	80.25%	79.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$90.00K	$90.00K
YoY Change
Total Long-Term Liabilities	$90.00K	$90.00K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.150M	$1.150M	$638.0K
Total Long-Term Liabilities	$90.00K	$90.00K	$0.00
Total Liabilities	$1.244M	$1.240M	$638.0K
YoY Change	94.98%	93.75%
SHAREHOLDERS EQUITY
Retained Earnings	$13.40M
YoY Change
Common Stock	$43.00K		$31.00K
YoY Change	38.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.980M	$9.980M	$807.0K
YoY Change
Total Liabilities & Shareholders Equity	$11.22M	$11.22M	$1.445M
YoY Change	676.75%	673.79%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$6.496M	-$6.496M	-$2.614M
YoY Change	148.51%	148.51%	107.79%
Depreciation, Depletion And Amortization	$20.00K	$23.00K	$10.00K
YoY Change	100.0%	109.09%	0.0%
Cash From Operating Activities	-$5.710M	-$5.714M	-$1.610M
YoY Change	254.66%	171.71%	973.33%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$48.00K	$30.00K
YoY Change	66.67%	33.33%
Acquisitions
YoY Change
Other Investing Activities	-$20.00K	-$20.00K
YoY Change
Cash From Investing Activities	-$70.00K	-$66.00K	-$30.00K
YoY Change	133.33%	83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.88M	$14.88M	10.00K
YoY Change	148700.0%	406.43%
NET CHANGE
Cash From Operating Activities	-5.710M	-$5.714M	-1.610M
Cash From Investing Activities	-70.00K	-$66.00K	-30.00K
Cash From Financing Activities	14.88M	$14.88M	10.00K
Net Change In Cash	9.100M	$9.099M	-1.630M
YoY Change	-658.28%	1038.8%	986.67%
FREE CASH FLOW
Cash From Operating Activities	-$5.710M	-$5.714M	-$1.610M
Capital Expenditures	$50.00K	$48.00K	$30.00K
Free Cash Flow	-$5.760M	-$5.762M	-$1.640M
YoY Change	251.22%	169.38%	993.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41502
CY2022	dei	Entity Registrant Name EntityRegistrantName	Wearable Devices Ltd.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Ha-Tnufa Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Yokne’am Illit,
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2066736
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Israel
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, NIS 0.01 par value per share
CY2022	dei	Trading Symbol TradingSymbol	WLDS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15049720	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1185
CY2022	dei	Auditor Name AuditorName	BDO Member Firm
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10373000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1274000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	54000	usd
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	62000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	543000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	47000	usd
CY2022Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	6000	usd
CY2021Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	11000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10976000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1402000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	248000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	43000	usd
CY2022Q4	us-gaap	Assets Assets	11224000	usd
CY2021Q4	us-gaap	Assets Assets	1445000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	156000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	72000	usd
CY2022Q4	wlds	Advance From Customers AdvanceFromCustomers	353000	usd
CY2021Q4	wlds	Advance From Customers AdvanceFromCustomers	273000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	24000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	416000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	222000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	47000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1150000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	638000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	94000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1244000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	638000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15049720	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15049720	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11136850	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11136850	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	43000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23346000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7689000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13409000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6913000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9980000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	807000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11224000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1445000	usd
CY2022	us-gaap	Revenues Revenues	45000	usd
CY2021	us-gaap	Revenues Revenues	142000	usd
CY2020	us-gaap	Revenues Revenues	57000	usd
CY2022	us-gaap	Cost Direct Material CostDirectMaterial	10000	usd
CY2021	us-gaap	Cost Direct Material CostDirectMaterial	10000	usd
CY2020	us-gaap	Cost Direct Material CostDirectMaterial	9000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2271000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1411000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	743000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1370000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	665000	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	287000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1948000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	628000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	174000	usd
CY2022	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses	904000	usd
CY2021	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses	97000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6458000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2669000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1156000	usd
CY2022	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	-38000	usd
CY2021	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	55000	usd
CY2020	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	-102000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6496000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2614000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1258000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1697000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	67000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1258000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2888000	usd
CY2021	wlds	Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost	2925000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3072000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2021	wlds	Stock Issued During Period Value Of Payment On Behalf Of Shares Issued StockIssuedDuringPeriodValueOfPaymentOnBehalfOfSharesIssued	-12000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2614000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	807000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	807000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1600	usd
CY2022	wlds	Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Public Offering Net IssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPublicOfferingNet	14319000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	400000	usd
CY2022	wlds	Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants IssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants	160000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6496000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9980000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6496000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2614000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1258000	usd
CY2022	us-gaap	Depreciation Depreciation	23000	usd
CY2021	us-gaap	Depreciation Depreciation	11000	usd
CY2020	us-gaap	Depreciation Depreciation	7000	usd
CY2021	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities	20000	usd
CY2020	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities	56000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	67000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12000	usd
CY2022	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	-8000	usd
CY2021	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	11000	usd
CY2020	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	51000	usd
CY2022	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	496000	usd
CY2021	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	30000	usd
CY2020	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	11000	usd
CY2022	wlds	Increase In Advance Payments IncreaseInAdvancePayments	79000	usd
CY2021	wlds	Increase In Advance Payments IncreaseInAdvancePayments	63000	usd
CY2020	wlds	Increase In Advance Payments IncreaseInAdvancePayments	210000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-41000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	194000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	119000	usd
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-72000	usd
CY2021	wlds	Increasedecrease In Advance Payments On Governmental Grant IncreasedecreaseInAdvancePaymentsOnGovernmentalGrant	42000	usd
CY2020	wlds	Increasedecrease In Advance Payments On Governmental Grant IncreasedecreaseInAdvancePaymentsOnGovernmentalGrant	-42000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	99000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-30000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5714000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2103000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1089000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
CY2022	wlds	Prepayments Of Leasing PrepaymentsOfLeasing	18000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16000	usd
CY2022	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli	14319000	usd
CY2021	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost	2925000	usd
CY2022	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs	500000	usd
CY2022	wlds	Refund To Safe Investors RefundToSAFEInvestors	100000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	usd
CY2022	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants	160000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2021	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares	12000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14879000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2938000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9099000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	799000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1105000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1274000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	475000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10373000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1274000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	475000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
CY2022	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity	400000	usd
CY2022	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability	229000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	13400000	usd
CY2022Q3	wlds	Warrants Exercise Into Ordinary Shares WarrantsExerciseIntoOrdinaryShares	40000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40000	shares
CY2022	wlds	Gross Proceeds GrossProceeds	16000000	usd
CY2022	wlds	Underwriting Net Proceed UnderwritingNetProceed	14900000	usd
CY2022	wlds	Underwriting Discounts And Commissions UnderwritingDiscountsAndCommissions	1100000	usd
CY2023Q1	us-gaap	Share Price SharePrice	0.54
CY2023Q1	wlds	Warrant Price WarrantPrice	0.09
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt"><b>b.</b></span></td> <td style="padding-right: 3pt"><span style="font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as to disclose contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. On an ongoing basis, management evaluates its estimates, judgments and assumptions. Management bases its estimates, judgments and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0"> </p>
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.08	pure
CY2022	wlds	Rate Of Monthly Severance Percentage RateOfMonthlySeverancePercentage	0.0833	pure
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	140000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	92000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	49000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt"><b>r.</b></span></td> <td><span style="font-size: 10pt"><b>Concentration of Credit Risk</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company maintains certain cash balances in a well-known Israeli bank.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022	wlds	Grants Received Equal Percentage Rate GrantsReceivedEqualPercentageRate	1	pure
CY2018Q4	wlds	Amounts Received Aggregate Amount AmountsReceivedAggregateAmount	1224000	usd
CY2021Q3	wlds	Total Expenses Of Iia Plan TotalExpensesOfIIAPlan	598000	usd
CY2022	wlds	Total Cash Received From The Iia TotalCashReceivedFromTheIIA	544000	usd
CY2022	wlds	Except Transfer Production Right ExceptTransferProductionRight	0.10	pure
CY2022	wlds	Production Transferred ProductionTransferred	0.10	pure
CY2022	wlds	Pay Increased Royalties Description PayIncreasedRoyaltiesDescription	the Company would be required to pay increased royalties, which usually amount to 1% in addition to the standard royalties rate 3%-3.5%, and also the total amount of its liability to the IIA may be increased to between 120% and 300% of the grants received from the IIA, depending on the manufacturing volume that is performed outside Israel (less royalties already paid to IIA).
CY2022	wlds	Marketing Grant Received MarketingGrantReceived	1	pure
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	102000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5000	usd
	wlds	Lease Payment Increased LeasePaymentIncreased	0.10	pure
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	74000	usd
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000	usd
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	600000	usd
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2019Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200000	usd
CY2019Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.04	pure
CY2022	wlds	Ordinary Shares Par Value OrdinarySharesParValue	0.01
CY2019Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1500000	usd
CY2022	wlds	Convertible Security Description ConvertibleSecurityDescription	The beneficial conversion feature of each one of convertible security was valued at zero.
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	300000	usd
CY2022Q2	wlds	Premoney Valuation Amount PremoneyValuationAmount	26400000	usd
CY2021Q2	wlds	Warrant Price Per Share Percentage WarrantPricePerSharePercentage	0.80	pure
CY2021Q2	wlds	Purchase Price Per Share PurchasePricePerShare	2.25
CY2021Q2	wlds	Purchase Price Per Share PurchasePricePerShare	2.25
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2
CY2022Q3	us-gaap	Other Borrowings OtherBorrowings	800000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1000000	usd
CY2022Q3	wlds	Aggregate Amount AggregateAmount	800000	usd
CY2022Q3	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.04	pure
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.22
CY2022	wlds	Vesting Periods VestingPeriods	P3Y
CY2021Q4	wlds	Issuance Of Shares Options IssuanceOfSharesOptions	22205	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.25
CY2021Q4	wlds	Termination Period TerminationPeriod	P10Y
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2021Q4	wlds	Share Based Compensation Options ShareBasedCompensationOptions	420090	shares
CY2021Q2	wlds	Ordinary Shares Warrant Exercisable OrdinarySharesWarrantExercisable	671687	shares
CY2022	wlds	Saf Es Amount SAFEsAmount	500000	usd
CY2022	wlds	Investor Investor	5
CY2022	wlds	Investor Amount InvestorAmount	100000	usd
CY2022	wlds	Converted Amount ConvertedAmount	400000	usd
CY2022Q4	wlds	Converted To Ordinary Shares ConvertedToOrdinaryShares	118204	shares
CY2022Q4	us-gaap	Cash Cash	100000	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	25000	usd
CY2022Q3	wlds	Investors Exercised Warrants InvestorsExercisedWarrants	40000	shares
CY2022Q4	wlds	Investors Exercised Warrants InvestorsExercisedWarrants	4666	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	863264	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.614
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	765576	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.55
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	145000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.184
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	351000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.323
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4666	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	241533	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15334	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.003
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11779	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.003
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	988264	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.563
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	863264	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.614
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	753236	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.703
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	564846	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.92
CY2021Q4	wlds	Options Valued Amount OptionsValuedAmount	932000	usd
CY2021Q4	wlds	Vesting Periods VestingPeriods	P3Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	2.53
CY2021Q2	wlds	Exercise Price Per Share ExercisePricePerShare	2.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.39	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016	pure
CY2022	wlds	Initial Exercise Percentage InitialExercisePercentage	50	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022Q1	wlds	Issuance Of Shares Options IssuanceOfSharesOptions	105000	shares
CY2022Q1	wlds	Exercise Price Per Share ExercisePricePerShare	0.003
CY2022Q1	wlds	Termination Period TerminationPeriod	P10Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	2.8
CY2022Q1	wlds	Options Expenses OptionsExpenses	294000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2022Q4	wlds	Exercise Price Per Share ExercisePricePerShare	0.66
CY2022Q4	wlds	Issuance Of Shares Options IssuanceOfSharesOptions	40000	shares
CY2022Q4	wlds	Options To Purchase Of Ordinary Shares OptionsToPurchaseOfOrdinaryShares	30000	shares
CY2022Q4	wlds	Termination Period TerminationPeriod	P10Y
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2022Q4	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	0.29	usd
CY2022Q4	wlds	Options Expenses OptionsExpenses	20000	usd
CY2022Q4	wlds	Vesting Periods VestingPeriods	P3Y
CY2022Q4	wlds	Option To Ordinary Shares OptionToOrdinaryShares	424653	shares
CY2022Q4	us-gaap	Shares Held In Employee Stock Option Plan Allocated SharesHeldInEmployeeStockOptionPlanAllocated	2257458	shares
CY2022	wlds	Options Expire Term OptionsExpireTerm	P10Y
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	67000	usd
CY2022Q4	wlds	Exercise Price Of Warrants ExercisePriceOfWarrants	4
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y
CY2022	wlds	Warrant Be Reduced To An Exercise Price Percentage WarrantBeReducedToAnExercisePricePercentage	0.50	pure
CY2022	wlds	Initial Exercise Price Percentage InitialExercisePricePercentage	0.50	pure
CY2022	wlds	Weighted Average Price Percentage WeightedAveragePricePercentage	1	pure
CY2022Q4	us-gaap	Share Price SharePrice	2
CY2021	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli		usd
CY2020	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli		usd
CY2022	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost		usd
CY2020	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost		usd
CY2021	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs		usd
CY2020	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs		usd
CY2021	wlds	Refund To Safe Investors RefundToSAFEInvestors		usd
CY2020	wlds	Refund To Safe Investors RefundToSAFEInvestors		usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2000000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q1	wlds	Officer Employee Monthly Salary OfficerEmployeeMonthlySalary	70000	ils
CY2022Q1	wlds	Related Party Monthly Salary RelatedPartyMonthlySalary	21000	usd
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6459910	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9709590	shares
CY2022	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities		usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	wlds	Increasedecrease In Advance Payments On Governmental Grant IncreasedecreaseInAdvancePaymentsOnGovernmentalGrant		usd
CY2021	wlds	Prepayments Of Leasing PrepaymentsOfLeasing		usd
CY2020	wlds	Prepayments Of Leasing PrepaymentsOfLeasing		usd
CY2021	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants		usd
CY2020	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares		usd
CY2020	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares		usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity		usd
CY2020	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity		usd
CY2021	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability		usd
CY2020	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability		usd
CY2022	wlds	Sales And Marketing Expenses SalesAndMarketingExpenses		usd
CY2022	wlds	Warrants Exercisable Term WarrantsExercisableTerm	P5Y
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001887673

Files In Submission

Name	View Source	Status
0001213900-23-022124-index-headers.html	Edgar Link	pending
0001213900-23-022124-index.html	Edgar Link	pending
0001213900-23-022124.txt	Edgar Link	pending
0001213900-23-022124-xbrl.zip	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex15-1_002.jpg	Edgar Link	pending
wlds-20221231_lab.xml	Edgar Link	unprocessable
f20f2022ex12-1_wearable.htm	Edgar Link	pending
f20f2022ex12-2_wearable.htm	Edgar Link	pending
f20f2022ex13-1_wearable.htm	Edgar Link	pending
f20f2022ex13-2_wearable.htm	Edgar Link	pending
f20f2022ex15-1_wearable.htm	Edgar Link	pending
f20f2022ex2-5_wearable.htm	Edgar Link	pending
f20f2022_wearable.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
f20f2022_wearable_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wlds-20221231.xsd	Edgar Link	pending
wlds-20221231_def.xml	Edgar Link	unprocessable
wlds-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
wlds-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WLDS
Wearable Devices Ltd. Stock $wlds

2022 Q4 Form 20-F Financial Statement

#000121390023022124 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WLDS Wearable Devices Ltd. Stock $wlds

2022 Q4 Form 20-F Financial Statement

#000121390023022124 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WLDS
Wearable Devices Ltd. Stock $wlds